Company webinar

Tryptamine Therapeutics (ASX:TYP)

Watch our webinar with Tryptamine Therapeutics, featuring CEO Jason Carroll. A presentation followed by live Q&A with the audience.

Date
August 28, 2024
Time
Where
Online
Entry
Free
Jason Carroll
Jason Carroll
CEO, Tryptamine Therapeutics (ASX:TYP)

About the company

Tryptamine Therapeutics Limited (ASX: TYP) is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.

Key topics

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →